slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 31,561-31,590
Pages 1,935
Rows per page 30
Slide function
31,561-31,590 of 58,039
18
Waterfall plot is a standard clinical trial visualization for tumor response.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
The chart uses a swimmer plot format to track longitudinal patient data including lymphodepletion status, response type, and survival.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
21
Includes waterfall plot of target lesion changes and Kaplan-Meier plots for PFS and OS.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
23
The slide uses a scatter plot format with a shared legend for patient IDs and dose levels.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
24
Data shows patient-specific longitudinal tracking of transgene copies/µg gDNA.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
25
Patients with baseline levels of SMRP in normal range were excluded. Data cutoff: September 9, 2022.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
27
The chart displays individual patient responses, with multiple patients achieving significant tumor regression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
30
The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
09
The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
10
The table displays counts and percentages of subjects experiencing specific adverse events. 'MAD' stands for Multiple Ascending Dose.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
11
The chart tracks neutrophil levels across multiple cohorts (placebo, 200mg QD, 200mg Q12H, 400mg Q12H, 500mg QD FED) from Day 1 to Day 70/EOS, with a vertical line marking the end of treatment at Day 14.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
12
The slide includes a disclaimer that cross-study comparisons are unreliable due to differences in study design.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
13
Includes two line charts: one normalized to baseline and one showing absolute values.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
22
DART stands for developmental and reproductive toxicology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
23
SAD = Single Ascending Dose; FE = Food Effect; PK = Pharmacokinetics; SAE = Serious Adverse Event; AE = Adverse Event; PBO = Placebo.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
24
MAD = Multiple Ascending Dose study. Data shows transient changes in reticulocytes and hemoglobin levels during treatment.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
07
Data source: Kelley Blue Book 2022.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · Market Size1 hit
05
The slide uses a before-after comparison for five business metrics, highlighting performance changes in a difficult macro environment.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Before After1 hit
09
The slide uses red lines/bars to highlight current period (2Q22) performance against historical trends.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · Satisfaction1 hit
11
The slide uses a waterfall chart to explain the variance in net profit between two periods, with detailed callouts for specific line items.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
12
Includes a detailed disclaimer regarding allocation methodology and exclusions.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
13
Includes waterfall-style comparison charts for Profit before tax and Total revenues.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
14
Includes waterfall-style charts for Profit before tax and Total revenues to highlight gains on sales.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
15
Includes waterfall-style bridge annotations on bar charts for Profit before tax and Total revenues.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
16
Includes waterfall-style growth indicators for PBT and Total Revenues.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · VisualizationLoop · Zoom In1 hit
17
The chart illustrates the bridge between two quarters of CET1 capital ratios.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit
21
The table highlights 2Q22 in a shaded column. Footnote indicates 2Q22 includes 221m net litigation expenses.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit
22
Includes specific callouts for litigation-related adjustments in the Americas region.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit
23
Includes specific adjustments for litigation and strategic exits.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit